Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antibody Structure01:10

Antibody Structure

59.0K
Overview
Antibodies, also known as immunoglobulins (Ig), are essential players of the adaptive immune system. These antigen-binding proteins are produced by B cells and make up 20 percent of the total blood plasma by weight. In mammals, antibodies fall into five different classes, which each elicits a different biological response upon antigen binding.
The Y-Shaped Structure of Antibodies Consists of Four Polypeptide Chains
Antibodies consist of four polypeptide chains: two identical heavy...
59.0K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Real-world comparative effectiveness of first-line BTK inhibitors in chronic lymphocytic leukemia.

Future oncology (London, England)·2026
Same author

Dual-functional Nanocarrier for Improved Immunochemotherapy of Acute Myeloid Leukemia.

Research square·2026
Same author

EpiMII: Structure-Aware Graph Neural Networks for MHC-II Epitope Generation.

Research (Washington, D.C.)·2026
Same author

Risk stratification of low-dose cytarabine and venetoclax in patients with AML ineligible for intensive chemotherapy.

Blood advances·2026
Same author

Risk stratification of low-dose cytarabine and venetoclax in patients with AML ineligible for intensive chemotherapy.

Blood advances·2025
Same author

Outcomes of patients treated with venetoclax plus azacitidine versus azacitidine alone stratified by advanced age and acute myeloid leukemia composite model.

Leukemia·2025

Related Experiment Video

Updated: Jun 5, 2025

Characterization of Glycoproteins with the Immunoglobulin Fold by X-Ray Crystallography and Biophysical Techniques
08:58

Characterization of Glycoproteins with the Immunoglobulin Fold by X-Ray Crystallography and Biophysical Techniques

Published on: July 5, 2018

12.6K

Structural insight into CD20/CD3-bispecific antibodies by molecular modeling.

Ze-Yu Sun1, Tianjian Liang1, Yiyang Zhang1

  • 1Department of Pharmaceutical Sciences, Computational Chemical Genomics Screening Center, and Pharmacometrics & System Pharmacology PharmacoAnalytics, School of Pharmacy, National Center of Excellence for Computational Drug Abuse Research, University of Pittsburgh, Pittsburgh, PA 15261, United States.

Computers in Biology and Medicine
|December 14, 2024
PubMed
Summary

This study improved a computational method to analyze how bispecific T cell engagers (TCEs) bind to CD3 targets. This enhances understanding of antibody interactions for better immunotherapy design against Non-Hodgkin's Lymphoma.

Keywords:
Bispecific antibodiesCD3MCCS-DockerNHL

More Related Videos

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody
07:36

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody

Published on: May 16, 2020

5.2K
In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
07:25

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis

Published on: May 4, 2017

17.7K

Related Experiment Videos

Last Updated: Jun 5, 2025

Characterization of Glycoproteins with the Immunoglobulin Fold by X-Ray Crystallography and Biophysical Techniques
08:58

Characterization of Glycoproteins with the Immunoglobulin Fold by X-Ray Crystallography and Biophysical Techniques

Published on: July 5, 2018

12.6K
Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody
07:36

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody

Published on: May 16, 2020

5.2K
In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
07:25

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis

Published on: May 4, 2017

17.7K

Area of Science:

  • Hematology
  • Immunology
  • Computational Biology

Background:

  • Non-Hodgkin's Lymphoma (NHL) treatment faces challenges with conventional therapies.
  • Bispecific T cell engagers (TCEs) show promise in immunotherapy but have associated adverse events.
  • Understanding structural interactions of TCEs with target proteins is vital for optimizing efficacy and safety.

Purpose of the Study:

  • To refine the MCCS-Docker protocol for analyzing protein-protein interactions.
  • To investigate the structural details of CD3 interactions with various therapeutic antibodies.
  • To identify key residues involved in the binding interface of TCEs with CD3.

Main Methods:

  • Utilized an updated MCCS-Docker protocol for computational modeling.
  • Performed docking studies to predict binding poses of antibodies to CD3.
  • Conducted molecular dynamics simulations to validate interaction stability.

Main Results:

  • Validated the effectiveness of the updated MCCS-Docker protocol.
  • Revealed detailed binding interactions between specific bispecific antibodies and CD3.
  • Identified key Tyrosine and Asparagine residues in antibodies critical for CD3 binding.

Conclusions:

  • The study provides a novel method for predicting critical residues in protein-protein interactions.
  • Enhanced understanding of structural determinants governing TCE-CD3 interactions.
  • Offers insights for designing improved immunotherapeutic agents for hematologic malignancies like NHL.